These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 22430630

  • 1. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.
    Lucarelli G, Fanelli M, Larocca AM, Germinario CA, Rutigliano M, Vavallo A, Selvaggi FP, Bettocchi C, Battaglia M, Ditonno P.
    Prostate; 2012 Nov; 72(15):1611-21. PubMed ID: 22430630
    [Abstract] [Full Text] [Related]

  • 2. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer.
    Lucarelli G, Rutigliano M, Bettocchi C, Palazzo S, Vavallo A, Galleggiante V, Trabucco S, Di Clemente D, Selvaggi FP, Battaglia M, Ditonno P.
    J Urol; 2013 Dec; 190(6):2271-7. PubMed ID: 23665271
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K, Hoesel W, Reiche J, Deger S, Kramer J, Loening SA, Lein M, Stephan C.
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001 Feb; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 11. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X, Truan D, Alcover J, Quintó L, Molina R, Luque P, Coca F, Ballesta AM.
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [Abstract] [Full Text] [Related]

  • 14. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y, Ozono S, Kagebayashi Y, Yoshi M, Tani Y, Uemura H, Momose H, Okajima E.
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [Abstract] [Full Text] [Related]

  • 15. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z, Jieming L, Su L, Wenlu S.
    J Surg Oncol; 2007 Jul 01; 96(1):54-61. PubMed ID: 17345593
    [Abstract] [Full Text] [Related]

  • 16. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 17. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F.
    Eur Urol; 2012 Mar 15; 61(3):455-66. PubMed ID: 22078333
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K.
    Cancer; 2005 Sep 01; 104(5):993-1003. PubMed ID: 16007682
    [Abstract] [Full Text] [Related]

  • 20. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug 01; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.